BIOVINC, LLC
bone-targeted bisphosphonate-fluoroquinolone conjugate molecules for treating infected bone fractures
- Sector
- Biotech
- Headquarters
- Santa Barbara, CA
- Total capital
- $10.9M
- Federal grants
- $10.8M
- 17 awards · 2015–2025
- Rank in peer group#46 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $45K
- 3 awards · Veterans Affairs
- Rank in Biotech#359 of 4373
- Granted patents
- 1
- 7 pending · first 2026
- Rank in peer group#186 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures$993K
- Federal grantHealth and Human S · Phase II · A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures$979K
- Federal grantHealth and Human S · Phase I · A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures$297K
- Federal grantHealth and Human S · Phase II · Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$989K
- Federal grantHealth and Human S · Phase II · Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$976K
- Federal grantHealth and Human S · Phase II · Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$999K
- Federal grantHealth and Human S · Phase I · Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer$225K
Show 13 earlier federal awards
- Federal grantHealth and Human S · Phase II · Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment$750K
- Federal grantHealth and Human S · Phase II · Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$692K
- Federal grantHealth and Human S · Phase I · Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis$225K
- Federal grantHealth and Human S · Phase II · Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$749K
- Federal grantHealth and Human S · Phase II · Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment$1.5M
- Federal contractVeterans Affairs · Lab Research Compounds$15K
- Federal grantHealth and Human S · Phase II · Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$741K
- Federal contractVeterans Affairs · 5-FAM-ZOL 3X1000NMOL$14K
- Federal grantHealth and Human S · Phase I · Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy$181K
- Federal contractVeterans Affairs · Research Compounds$16K
- Federal grantHealth and Human S · Phase I · Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment$150K
- Federal grantHealth and Human S · Phase I · Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ$150K
- Federal grantHealth and Human S · Phase I · Novel Bisphosphonate 18F-PET and PET/optical Dual Modality Probes for Rheumatoid Arthritis Imaging$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#46 · top 9%
- Granted patents#186 · top 36%
- Linked publications#14 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 8- GrantedBisphosphonate Quinolone Conjugates And Uses ThereofUSPTOUS 12,624,057
- PendingBisphosphonate Quinolone Conjugates And Uses ThereofUSPTOApplication PCTUS2019041063
- PendingBisphosphonate Quinolone Conjugates And Uses ThereofUSPTOApplication 62695583
Show all 8 patent records
- Bisphosphonate Quinolone Conjugates And Uses ThereofMay 12, 2026 · US 12,624,057Granted
- Bisphosphonate Quinolone Conjugates And Uses ThereofApplication PCTUS2019041063Pending
- Bisphosphonate Quinolone Conjugates And Uses ThereofApplication 62695583Pending
- Skeletal Removal Of BisphosphonatesApplication PCTUS2017035169Pending
- Bisphosphonate Quinolone Bioconjugates And Uses ThereofApplication 62448060Pending
- Bisphosphonate Quinolone Bioconjugates And Uses ThereofApplication 62357727Pending
- Bone Targeted Therapeutics And DiagnosticsApplication 62345370Pending
- Skeletal Removal of BisphosphonatesApplication 62344245Pending
Recent research by its founders
- Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells20260 cites
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells20260 cites
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition20252 cites
Related companies, and why
- Ichor Life Sciences, Inc.Similar federal contract value in Biotech · $47K in contracts
- PUMA BIOTECHNOLOGY, INC.Similar federal contract value in Biotech · $47K in contracts
- Miromatrix Medical Inc.Similar federal contract value in Biotech · $46K in contracts
- Vaxxinity, Inc.Similar federal contract value in Biotech · $39K in contracts
- CELL BIOLOGICS INCSimilar federal contract value in Biotech · $37K in contracts
- EPIGENOME TECHNOLOGIES, INC.Similar federal contract value in Biotech · $35K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .